Aesica Pharmaceuticals Relocates Services to Queenborough

January 21, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016, Volume 12, Issue 2

Aesica Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO), announced the strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough. The new development center at Queenborough has more than twice the capacity of the existing one in Nottingham.

Aesica Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO), announced the strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough. The new development center at Queenborough has more than twice the capacity of the existing one in Nottingham.

According to a Jan. 19, 2016 press announcement from the company, Aesica will now provide full manufacturing and development services at its Queenborough site with the addition of a new development center. From Queenborough, the company now provides API production, formulation development, and clinical manufacture through to commercial-scale product manufacturing.

The new development center will be able to handle potent and controlled drugs, which mirror the commercial offering from Queenborough. The company will also still offer semi-solid development and inhalation services. 

Source: Aesica Pharmaceuticals

 

Related Content:

PharmTech News | Supplier News